Brought to you by 
Genentech, Inspire sign respiratory drug alliance
10 Apr 2020
Executive Summary
In a collaboration to develop respiratory therapeutics, Genentech could pay Inspire Pharmaceuticals (mucosal hydration and epithelial cell therapeutics based on P2Y receptors) up to $78mm including $10mm in cash and $5mm in equity up front, plus milestones and royalties. Genentech gets worldwide rights, except in Japan, to lower respiratory therapeutics, and worldwide rights to drugs for upper airway disorders, such as sinusitis and otitis media.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech, Inspire sign respiratory drug alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice